🔗 Share this article

While the United States continues making sweeping changes to its vaccination recommendations, an unexpected name appears in a surprising turn: Høeg, an American of Danish descent sports medicine doctor and public health researcher who initially gained attention by expressing skepticism about Covid shots throughout the global health crisis and has zeroed in on potential deaths following COVID-19 vaccination in her short tenure at the Food and Drug Administration.

Planned Changes to Pediatric Immunization Program

Agency leaders planned to announce radical changes to the childhood immunization program earlier this month, bringing the US with the Danish national calendar, sources say – a major change that would put the US out of step with much of the global community with little proof for improved outcomes. The announcement has been pushed back until the next year.

In place of the top vaccines chief, Tracy Beth Høeg is scheduled to speak at the gathering. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth person to head the division this calendar year.

Consolidating Power at the FDA

This interim role could signify a tighter collaboration between the pharmaceutical and vaccine centers as Dr. Høeg and Prasad solidify control at the FDA – and it suggests a renewed priority upon rolling back already-approved vaccines at the FDA.

Dr. Høeg has frequently advocated for discontinuing certain pediatric shot schedules in the US to become more like Denmark's approach, a society with universal health coverage and a population approximately the size of the state of Wisconsin.

To date comments, she has kept her attention on immunizations – typically the responsibility of Dr. Prasad, chief of the FDA’s CBER – rather than drug regulation.

Concerns Over Background

Dr. Høeg has no obvious track record in medication creation, regulation or administrative roles, which has been standard for former directors of the CBER. She has been employed at the FDA as a key advisor to the commissioner and the vaccine center since spring.

“She doesn’t seem to have the requisite experience” for overseeing the CDER, remarked a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She has no expertise in running a sizeable institution. She has no expertise in drug approvals.”

Former commissioners of CBER would “understand laws and regulations and the underlying principles of pharmaceutical innovation”, noted a former acting FDA commissioner. “Clearly, she has not acquired the kind of background that prior appointees who headed the center have had.”

The drug center has an immense range of responsibilities at the FDA, the former commissioner stated.

“Many people just zeroes in on the novel medication approvals, but the off-patent medication office approves numerous generic drugs. There’s a biosimilars program, non-prescription drug unit and more, and every single one must be managed,” Woodcock said. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a substantial leadership aspect to the position, which oversees over 5,000 employees. “It is a massive administrative position, if you perform it correctly,” Woodcock added.

Agency Reaction and Contentious Initiatives

In response to concerns about Dr. Høeg's credentials and whether this appointment represents increased cooperation among agency officials on vaccines, a spokesperson stated that the “questions stem from inaccurate premises”.

“Her resume aligns with the responsibilities of her role,” the spokesperson said, pointing to the months Høeg spent guiding the FDA commissioner on “medication safety and regulatory science, including computational safety modeling and shot safety tracking”.

As the temporary head, Høeg assumes responsibility for the commissioner’s new fast-track approval initiative, a contentious rapid therapy clearance system that allegedly worried her preceding directors. “By what process are these therapies being selected for this voucher program? Who is making the decisions?” Dr. Howard questioned. “There is a lot of confidentiality happening at the FDA right now.”

In general, he remarked, “the FDA seems to be moving towards laxer rules of most medications, aside from vaccines.”

Public Past Work on Vaccines

Concerning vaccines, Dr. Høeg has a more established, if concerning, track record, some experts said. She published a research paper using non-validated crowd-sourced reports to assess the rate of myocarditis after Covid vaccination. She counseled the state of Florida top health official Dr. Joseph Ladapo, who reportedly have altered data to suggest Covid vaccinations are riskier than they are.

Included in her “desired changes” for the current government encompassed changing rules for new vaccines and discontinuing “non-essential” immunizations, she remarked following the vote on a audio program. At the agency, Dr. Høeg has reportedly proposed barring adolescent males from receiving Covid vaccines.

“She’s an complete dogmatist who commences with her preconceived notions and works backwards to accommodate the science in a very deceptive, fraudulent fashion,” Dr. Howard said.

Gaining Influence and a “Push for Payback”

Dr. Høeg became part of fellow contrarians, {like|